Navigation Links
VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
Date:8/25/2008

BOSTON, Aug. 25 /PRNewswire/ -- Scimitar Equity, LLC issues a review of VioQuest Pharmaceuticals, Inc (OTC Bulletin Board: VOQP), entitled, "Creating Value; Turnaround Leverages Product Opportunities while Expectation Abounds and Losses Decrease."

This review is available at website: http://www.scimitarequity.com

VioQuest Pharmaceuticals is a New Jersey-based biotechnology company dedicated to becoming a recognized leader in the successful development of novel drug therapies targeting both the molecular basis of cancer and side effects of treatment. VioQuest's oncology portfolio includes: Xyfid(TM) (1% uracil topical), for the treatment of dry skin conditions and manage the burning and itching associated with various dermatoses; VQD-002 (triciribine phosphate monohydrate), a targeted inhibitor of Akt activation; and Lenocta(TM) (sodium stibogluconate), an inhibitor of certain protein tyrosine phosphatases such as SHP-1, SHP-2, and PTP1B. Further information about VioQuest can be found at: http://www.vioquestpharm.com

Scimitar Equity, LLC provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about VioQuest Pharmaceuticals, Inc (OTC Bulletin Board: VOQP) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not ha
'/>"/>

SOURCE Scimitar Equity, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
2. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
3. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
6. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
7. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
8. Alseres Pharmaceuticals, Inc. Raises $5 Million
9. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
10. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
11. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 GenomeDx ... genomic analysis platform, successfully classified various subtypes ... expression of certain biomarkers, including one type ... this unique genomic signature has potential as ... neoadjuvant chemotherapy in patients with muscle-invasive bladder ...
(Date:6/1/2015)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced results ... 2015 first quarter financial statements and MD&A have been filed on ... March 31,(in CDN$,000 except per share data) , 2015 ... Gross profit , 1,531 , 329 Ebitda* , ... 528 , (531) Basic earnings (loss) per share ...
(Date:6/1/2015)... Research and Markets ( ... "Global PDT Machine Industry Report 2014" ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The Global ... and in-depth study on the current state of ... basic overview of the industry including definitions, classifications, ...
(Date:6/1/2015)... 01, 2015 Regis Technologies, Inc. ... of chiral stationary phases (CSPs) for analytical and ... current and presenting solutions for new clients, Regis ... This valuable addition to its core expertise in ... that can tackle projects for the scale clients ...
Breaking Biology Technology:GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3Global PDT Machine Industry Report 2014 2Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3
... workforce reduction, NEW YORK, April 4, 2008 ... that it is implementing a,strategic restructuring plan to ... efforts. The plan, which was prompted by the ... clinical trial of Sulonex(TM),(sulodexide) for the treatment of ...
... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), a ... that the first New Zealand patient,was treated with ... December 2007. A second patient was treated in ... drug-eluting stent for peripheral,arterial disease (PAD) and was ...
... held at the Society for Biomolecular Sciences 14th ... ... Ltd., an,international provider of microfluidic systems in the emerging field of,nano-lifesciences, ... enables researchers to execute physiologically,relevant flow experiments evaluating the adhesion of ...
Cached Biology Technology:Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 2Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 3Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan 4Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 2Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 3Angiotech announces commercial launch of Cook Medical's Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand 4Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays 2
(Date:5/19/2015)... YORK , May 19, 2015  Technology is ... both internally and in the cloud. Passwords and their ... use of OTP and standards-based specifications such as those ... the outmoded use of passwords presents for BYOD, COPE, ... a unified biometric identity protocol. In ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/7/2015)... 7, 2015 Fingerprint Cards ... and FPC1035, FPC,s smallest touch fingerprint sensors to ... considered for integration on the backside of the ... increased possibilities to integrate touch fingerprint sensors in ... improves possibilities for module manufacturers to customize the ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... a salt sea without an outlet, lies over 400 ... content because it increases their buoyancy. "For scientists, ... provides a diachronic view of its climate past," says ... Mineralogy and Paleontology at the University of Bonn. ...
... has developed a framework to evaluate the risk of ... paper based on this work: A framework for assessing ... been published in the Malaria Journal today. ... drug, so it is important when developing new medicines ...
... effort to document environmental change by monitoring and ... The country,s inclusion made it the newest ... Drilling Program (IODP). IODP scientists conduct research ... of the Earth through drilling, coring, monitoring and ...
Cached Biology News:Drastic desertification 2Drastic desertification 3MMV develops framework to assess risk of resistance for antimalarial compounds 2Brazil joins international marine research effort 2
... Introducing SilverSNAP Stain for Mass Spectrometry ... proteome, mass spectrometry (MS) has emerged as ... Silver staining of 2-D gels is now ... of procedures that leads ultimately to identification ...
... PCR System is the only PCR system ... and every time. It provides accuracy, consistency, ... source or the property of the DNA ... Enzyme Mix, a unique blend of thermostable ...
... cleaning agent for removing RNase ... and pipettors. It is ... contamination from microcentrifuge tubes without ... Zap (R) is ...
A set of five proteins which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: